Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BriaCell Therapeutics ( (TSE:BCT) ) just unveiled an update.
BriaCell Therapeutics has been awarded a $2 million grant from the US National Cancer Institute to advance its Bria-PROS+ immunotherapy for prostate cancer. This funding will support the manufacturing and Phase 1/2a clinical trial of Bria-PROS+, addressing the urgent unmet medical need in metastatic prostate cancer and validating BriaCell’s innovative approach to personalized cancer treatment.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$32.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care.
Average Trading Volume: 30,349
Technical Sentiment Signal: Sell
Current Market Cap: C$16.67M
For detailed information about BCT stock, go to TipRanks’ Stock Analysis page.